vTv Therapeutics Inc 8-K, filed Jun 15, 2020
vTv Therapeutics Inc. (VTVT)
About this 8-K
vTv Therapeutics Inc filed this 8-K on June 15, 2020, reporting on events of June 11, 2020.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): June 11, 2020
vTv Therapeutics Inc. (Exact name of registrant as specified in its charter)
| Delaware<br><br><br>(State or other jurisdiction<br><br><br>of incorporation) | 001-37524<br><br><br>(Commission File No.) | 47-3916571<br>(IRS Employer <br>Identification No.) |
|---|---|---|
| 3980 Premier Drive, Suite 310<br><br><br>High Point, NC 27265<br><br><br>(Address of principal executive offices) | ||
| --- |
(336) 841-0300
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a‑12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Class A common stock, par value $0.01 per share | VTVT | NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07 Submission of Matters to a Vote of Security Holders
On June 11, 2020, vTv Therapeutics Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:
| (1) | The Company’s stockholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a term to expire at the Company’s 2021 annual meeting of stockholders or until their successors are duly elected and qualified based on the following results of the voting: | |||||||
|---|---|---|---|---|---|---|---|---|
| Director Nominee | For | Against | Withheld | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Jeffrey B. Kindler | 59,531,174 | — | 150,874 | 5,947,754 | ||||
| John A. Fry | 59,593,955 | — | 88,093 | 5,947,754 | ||||
| Hersh Kozlov | 59,543,228 | — | 138,820 | 5,947,754 | ||||
| Paul G. Savas | 59,556,857 | — | 125,191 | 5,947,754 | ||||
| Noel J. Spiegel | 59,603,564 | — | 78,484 | 5,947,754 | ||||
| Howard L. Weiner | 59,602,155 | — | 79,893 | 5,947,754 | ||||
| (2) | An amendment to the Company’s 2015 Omnibus Equity Incentive Plan (the “Omnibus Incentive Plan”) to increase the number of authorized shares reserved for issuance under the Omnibus Incentive Plan was approved based on the following results of the voting: | |||||||
| --- | --- | |||||||
| For | Against | Withheld | Broker Non-Votes | |||||
| --- | --- | --- | --- | --- | --- | --- | --- | |
| 59,156,032 | 454,594 | 71,422 | 5,947,754 | |||||
| (3) | The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020 was ratified based on the following results of the voting: | |||||||
| --- | --- | |||||||
| For | Against | Abstain | ||||||
| --- | --- | --- | --- | --- | --- | |||
| 65,258,211 | 328,705 | 42,886 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
VTV THERAPEUTICS INC.
| By: | /s/ Rudy C. Howard |
|---|---|
| Name: | Rudy C. Howard |
| Title: | Chief Financial Officer |
Dated: June 15, 2020